Evidence map›Paper›PMID 24587248›Full record

ArticlePloS one2014

Mebendazole reduces vascular smooth muscle cell proliferation and neointimal formation following vascular injury in mice.

Jintao Wang, Hui Wang, Chiao Guo, Wei Luo, Alyssa Lawler, Aswin Reddy, Julia Wang, Eddy B Sun, Daniel T Eitzman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jintao WangUniversity of Michigan, Department of Internal Medicine, Cardiovascular Research Center, Ann Arbor, Michigan, United States of America.
Hui WangUniversity of Michigan, Department of Internal Medicine, Cardiovascular Research Center, Ann Arbor, Michigan, United States of America.
Chiao GuoUniversity of Michigan, Department of Internal Medicine, Cardiovascular Research Center, Ann Arbor, Michigan, United States of America.
Wei LuoUniversity of Michigan, Department of Internal Medicine, Cardiovascular Research Center, Ann Arbor, Michigan, United States of America.
Alyssa LawlerUniversity of Michigan, Department of Internal Medicine, Cardiovascular Research Center, Ann Arbor, Michigan, United States of America.
Aswin ReddyUniversity of Michigan, Department of Internal Medicine, Cardiovascular Research Center, Ann Arbor, Michigan, United States of America.
Julia WangUniversity of Michigan, Department of Internal Medicine, Cardiovascular Research Center, Ann Arbor, Michigan, United States of America.
Eddy B SunUniversity of Michigan, Department of Internal Medicine, Cardiovascular Research Center, Ann Arbor, Michigan, United States of America.
Daniel T EitzmanUniversity of Michigan, Department of Internal Medicine, Cardiovascular Research Center, Ann Arbor, Michigan, United States of America.
Michigan United · USUniversity of Michigan–Ann Arbor · US

Funding

Leptin in Vascular DiseaseR01HL073150 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI EITZMAN, DANIEL T · 2003 to 2012
$3.3M
BLRD VA I01 BX000353NHLBI NIH HHS HL073150NHLBI NIH HHS R01 HL073150
6 · The paper itself

Abstract

Mebendazole is an antihelminthic drug that exerts its effects via interference with microtubule function in parasites. To determine the utility of mebendazole as a potential treatment for vascular diseases involving proliferation of vascular smooth muscle cells, the effects of mebendazole on vascular smooth muscle cell proliferation were tested in vitro and in a mouse model of arterial injury. In vitro, mebendazole inhibited proliferation and migration of murine vascular smooth muscle cells and this was associated with altered intracellular microtubule organization. To determine in vivo effects of mebendazole following vascular injury, femoral arterial wire injury was induced in wild-type mice treated with either mebendazole or placebo control. Compared with placebo-treated mice, mebendazole-treated mice formed less neointima at the site of injury. Mebendazole is effective at inhibiting vascular smooth muscle cell proliferation and migration, and neointimal formation following arterial injury in mice.

Indexed as

AnimalsApoptosisCell MovementCell ProliferationDisease Models, AnimalHyperplasiaMaleMebendazoleMiceMuscle, Smooth, VascularMyocytes, Smooth MuscleNeointimaVascular System InjuriesMebendazole

Identifiers

PMID24587248
PMCPMC3937425
OpenAlexW2059170872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.